Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use
Keratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA i...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Case Reports in Pathology |
Online Access: | http://dx.doi.org/10.1155/2017/8257590 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832565272443092992 |
---|---|
author | Jason E. Cohn Hilary M. Caruso Sales Giang Huong Nguyen Harvey Spector Kenneth Briskin |
author_facet | Jason E. Cohn Hilary M. Caruso Sales Giang Huong Nguyen Harvey Spector Kenneth Briskin |
author_sort | Jason E. Cohn |
collection | DOAJ |
description | Keratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA involving the nasal septum, possibly related to ranibizumab use. A flesh-colored lesion on the right anterior nasal septum lesion was visualized on examination. Histologic examination revealed a well-circumscribed, dome-shaped central crater filled with keratin, well-differentiated squamous epithelium with ground-glass cytoplasm with pushing margins, and intraepithelial microabscesses establishing the diagnosis of KA. KA of the nasal septum has only been reported once in the literature. This case is unusual because it normally presents on sun-exposed areas. Additionally, this patient was taking ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor for macular degeneration. Despite ranibizumab not being directly linked to precancerous and cancerous skin lesions, agents in this medication class have been. Although it is difficult to prove associations in this isolated case, the role of ranibizumab causing cutaneous lesions should be further investigated. |
format | Article |
id | doaj-art-ee7bb8c6894f4ababd06ebfdc1b108b9 |
institution | Kabale University |
issn | 2090-6781 2090-679X |
language | English |
publishDate | 2017-01-01 |
publisher | Wiley |
record_format | Article |
series | Case Reports in Pathology |
spelling | doaj-art-ee7bb8c6894f4ababd06ebfdc1b108b92025-02-03T01:08:55ZengWileyCase Reports in Pathology2090-67812090-679X2017-01-01201710.1155/2017/82575908257590Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab UseJason E. Cohn0Hilary M. Caruso Sales1Giang Huong Nguyen2Harvey Spector3Kenneth Briskin4Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, 4190 City Line Avenue, Philadelphia, PA, USADepartment of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, 4190 City Line Avenue, Philadelphia, PA, USADepartment of Dermatology, University of Colorado Anschutz Medical College, 1665 Aurora Court, Aurora, CO, USADepartment of Pathology, Crozer-Chester Medical Center, One Medical Center Boulevard, Upland, PA, USADepartment of Otolaryngology-Head and Neck Surgery, Crozer-Chester Medical Center, One Medical Center Boulevard, Upland, PA, USAKeratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA involving the nasal septum, possibly related to ranibizumab use. A flesh-colored lesion on the right anterior nasal septum lesion was visualized on examination. Histologic examination revealed a well-circumscribed, dome-shaped central crater filled with keratin, well-differentiated squamous epithelium with ground-glass cytoplasm with pushing margins, and intraepithelial microabscesses establishing the diagnosis of KA. KA of the nasal septum has only been reported once in the literature. This case is unusual because it normally presents on sun-exposed areas. Additionally, this patient was taking ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor for macular degeneration. Despite ranibizumab not being directly linked to precancerous and cancerous skin lesions, agents in this medication class have been. Although it is difficult to prove associations in this isolated case, the role of ranibizumab causing cutaneous lesions should be further investigated.http://dx.doi.org/10.1155/2017/8257590 |
spellingShingle | Jason E. Cohn Hilary M. Caruso Sales Giang Huong Nguyen Harvey Spector Kenneth Briskin Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use Case Reports in Pathology |
title | Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use |
title_full | Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use |
title_fullStr | Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use |
title_full_unstemmed | Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use |
title_short | Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use |
title_sort | keratoacanthoma of the nasal septum secondary to ranibizumab use |
url | http://dx.doi.org/10.1155/2017/8257590 |
work_keys_str_mv | AT jasonecohn keratoacanthomaofthenasalseptumsecondarytoranibizumabuse AT hilarymcarusosales keratoacanthomaofthenasalseptumsecondarytoranibizumabuse AT gianghuongnguyen keratoacanthomaofthenasalseptumsecondarytoranibizumabuse AT harveyspector keratoacanthomaofthenasalseptumsecondarytoranibizumabuse AT kennethbriskin keratoacanthomaofthenasalseptumsecondarytoranibizumabuse |